期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Observational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer's disease ......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Neuronal hyperactivity related to beta-amyloid (A beta) is considered an early warning sign of Alzheimer disease (AD). Although increasing ......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Objective We aimed to investigate the associations between healthy lifestyles and Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). Me......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-beta (A beta) plaques and neurofibrillary tangles (NFTs). The amylo......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Introduction Subjective cognitive decline (SCD) represents a cognitively normal state but at an increased risk for developing Alzheimer's disease (AD)......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Blood circulating microRNAs that are specific for Alzheimer's disease (AD) can be identified from differentially expressed microRNAs (DEmiR......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background We aimed to investigate the tau biomarker discrepancies of Alzheimer's disease (AD) using plasma tau phosphorylated at threonine 181 (p-tau......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background: Accelerated long-term forgetting has been identified in preclinical Alzheimer's disease (AD) and is attributed to a selective impairment o......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Subjective cognitive decline (SCD) is the subjective perception of a decline in memory and/or other cognitive functions in the absence of o......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Plasma biomarkers showed a promising value in the disease diagnosis and management of Alzheimer's disease (AD). However, profiles of the bi......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
BackgroundAlzheimer's disease (AD) is an intractable neurodegenerative disorder in the elderly population, currently lacking a cure. Trichostatin A (T......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background Epidemiological studies link vascular disease risk factors such as atherosclerosis, hypertension, and diabetes mellitus with Alzheimer's di......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Challenges have been recognized in healthcare of patients with Alzheimer's disease (AD) in the COVID-19 pandemic, given a high infection and mortality......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
Background In recent years, excellent results have suggested an association between the "brain-gut" axis and Alzheimer's disease (AD) progression, yet......
期刊: ALZHEIMERS RESEARCH & THERAPY, 2021; 13 (1)
BackgroundType 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insuli......